Akcea Therapeutics

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. .

Ionis Pharma

Ionis With Akcea: Still A Bargain

NEW YORK, Sept. 26, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Ionis...

IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Investigations; Investors are Encouraged to Contact the Firm - AKCA, BLDR, DCOM, STND

NEW YORK, Sept. 25, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of AKCA to Ionis for $18.15 per share in cash. If you are a AKCA investor, and would like...

Lifshitz Law Firm, P.C. Announces Investigation of Akcea Therapeutics, Inc. (NASDAQ: AKCA), BMC Stock Holdings, Inc. (NASDAQ: BMCH), Builders FirstSource, Inc. (NASDAQ: BLDR), Cancer Genetics, Inc. (NASDAQ: CGIX), Cellular Biomedicine Group, Inc. (NASDAQ:

LONDON--(BUSINESS WIRE)--Akcea Therapeutics UK Ltd., a subsidiary of Akcea Therapeutics Inc.

WAYLIVRA▼® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in England

PHILADELPHIA, Sept. 5, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Akcea Therapeutics, Inc.

Kaskela Law LLC Announces Stockholder Investigation of Akcea Therapeutics, Inc. (AKCA) and Encourages Investors to Contact the Firm

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

AKCEA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akcea Therapeutics, Inc. - AKCA

NEW YORK, Sept. 1, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Akcea Therapeutics, Inc.

INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of Akcea Therapeutics, Inc. - AKCA

Ionis (IONS) is set to acquire the remaining 24% stake in Akcea Therapeutics (AKCA) in an all-cash deal.

Ionis to Acquire Remaining Stake in Akcea, Stocks Rally

SAN DIEGO, Sept. 1, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Akcea Therapeutics, Inc.

(AKCA) Alert: Johnson Fistel Investigates Proposed Sale of Akcea Therapeutics; Is $18.15 a Fair Price?

NEW YORK, Aug. 31, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akcea Therapeutics, Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Akcea Therapeutics, Inc.

The biotech is being acquired by its largest shareholder.

Why Akcea Therapeutics Stock Skyrocketed Today

(Newsfile Corp. - August 31, 2020) -  The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders.newsfilecorp.com/files/7091/62885_07ae7de5b4daaa4c_001full.jpgTo: All Persons or Entities who purchased Akc

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Akcea Therapeutics, Inc. to Ionis Pharmaceuticals, Inc.

Akcea Therapeutics Inc. (NASDAQ: AKCA) stock jumped on Monday after it was announced that Ionis Pharmaceuticals Inc.

What Akcea Shareholders Get in the Ionis Buyout

Akcea Therapeutics Inc (NASDAQ: AKCA) shares were rallying strongly Monday following a buyout deal.

Akcea Therapeutics Rallies After Majority Owner Ionis Agrees To Buy Remaining Stake

Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics

Akcea Therapeutics, Inc. (AKCA) CEO Damien McDevitt on Q2 2020 Results - Earnings Call Transcript

Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of -113.33% and -47.10%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Akcea Therapeutics (AKCA) Reports Q2 Loss, Misses Revenue Estimates

BOSTON, Aug. 4, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc.

Akcea Reports Financial Results and Highlights for Second Quarter 2020

Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Akcea Therapeutics (AKCA) Report Negative Earnings Next Week? What You Should Know

Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Akcea (AKCA) reports Q2 results.

Akcea (AKCA) to Report Q2 Earnings: What's in the Offing?

BOSTON, July 21, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc.

Akcea Therapeutics to Hold Second Quarter 2020 Financial Results Webcast

BOSTON, July 20, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc.

Akcea Appoints New Senior Vice President, Global Medical Affairs

BOSTON, July 9, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that William Andrews, MD, FACP, has joined the company as chief medical officer (CMO), effective immediately. Dr. Andrews will lead...

Akcea Announces Appointment of New Chief Medical Officer

Akcea Therapeutics (AKCA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Akcea Therapeutics (AKCA) Rating Upgrade to Strong Buy

BOSTON, June 17, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that Damien McDevitt, chief executive...

News for Akcea Therapeutics Stock (AKCA)